Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Collegium Pharmaceutical Inc COLL

Healthcare
Collegium Pharmaceutical, Inc. is a diversified specialty pharmaceutical company. The Company commercializes its pain portfolio, consisting of Xtampza extended-release (ER), Nucynta ER and Nucynta immediate-release (IR), Belbuca, and Symproic in the United States. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. Xtampza ER is a pain treatment option designed... see more

Recent & Breaking News (NDAQ:COLL)

Collegium Completes the Acquisition of BDSI

GlobeNewswire March 22, 2022

Collegium Reports Fourth Quarter and Full-Year 2021 Financial Results

GlobeNewswire February 24, 2022

BIODELIVERY SCIENCES INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioDelivery Sciences International, Inc. - BDSI

PR Newswire February 16, 2022

SHAREHOLDER ALERT: WeissLaw LLP Investigates BioDelivery Sciences International, Inc.

PR Newswire February 15, 2022

Collegium to Acquire BioDelivery Sciences in an All-Cash Deal

GlobeNewswire February 14, 2022

Collegium to Acquire BioDelivery Sciences Broadening Pain Portfolio

GlobeNewswire February 14, 2022

Collegium to Host Conference Call to Discuss Fourth Quarter and Full-Year 2021 Financial Results

GlobeNewswire February 10, 2022

Collegium Announces Settlement Framework to Resolve Pending Opioid-Related Litigation

GlobeNewswire December 28, 2021

Collegium Ranks as a Top Place to Work for 2021 by The Boston Globe

GlobeNewswire December 6, 2021

Collegium Announces $25 Million Accelerated Share Repurchase Program

GlobeNewswire November 15, 2021

UPDATE: Collegium to Participate in Upcoming Conferences

GlobeNewswire November 11, 2021

Collegium Participate in Upcoming Conferences

GlobeNewswire November 11, 2021

Collegium Reports Third Quarter Fiscal 2021 Results

GlobeNewswire November 4, 2021

Collegium to Host Conference Call to Discuss Third Quarter 2021 Financial Results and Provide Corporate Update

GlobeNewswire October 21, 2021

Collegium Announces Four Posters Presented at PAINWeek 2021 National Conference

GlobeNewswire September 13, 2021

Collegium to Participate in Upcoming Investor Conferences

GlobeNewswire September 1, 2021

Collegium Announces $100 Million Share Repurchase Program

GlobeNewswire August 16, 2021

Collegium Reports Strong Q2 Results with Cash Balance Growing to Over $200 Million

GlobeNewswire August 5, 2021

Collegium to Host Conference Call to Discuss Second Quarter 2021 Financial Results and Provide Corporate Update

GlobeNewswire July 21, 2021

Collegium Announces Publication of Real-World Data in Journal of Pain Research

GlobeNewswire June 16, 2021